menu
    • menu

    Company profile for Terremoto Biosciences

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped...
    Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Terremoto BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Tower Pl FL 17 South San Francisco, CA, 94080-1826
    Telephone
    Telephone
    (650) 240-8844
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://terremotobio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Terremoto Takes $108M Series C To Fuel Trials Of AKT1 Inhibitors
    Terremoto Takes $108M Series C To Fuel Trials Of AKT1 Inhibitors

    15 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/terremoto-takes-108m-series-c-fuel-clinical-trials-akt1-inhibitors

    FIERCE BIOTECH
    15 Apr 2026
    Share Share
    Terremoto Biosciences Names Charles Baum As CEO
    Terremoto Biosciences Names Charles Baum As CEO

    25 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240725098139/en

    BUSINESSWIRE
    25 Jul 2024
    Share Share
    Terremoto Biosciences Closes $175 Million Series B Financing
    Terremoto Biosciences Closes $175 Million Series B Financing

    02 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231102363483/en

    BUSINESSWIRE
    02 Nov 2023
    Share Share
    OrbiMed and Third Rock’s Terremoto Bio raises $175M for small molecule R&D
    OrbiMed and Third Rock’s Terremoto Bio raises $175M for small molecule R&D

    02 Nov 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/orbimed-and-third-rocks-terremoto-biosciences-raises-175m-for-small-molecule-rd/

    Kyle LaHucik ENDPTS
    02 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search